Hologic, Inc. $HOLX is Sound Shore Management Inc CT’s 9th Largest Position

Sound Shore Management Inc CT lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,337,653 shares of the medical equipment provider’s stock after selling 45,037 shares during the period. Hologic accounts for approximately 3.0% of Sound Shore Management Inc CT’s investment portfolio, making the stock its 9th largest holding. Sound Shore Management Inc CT owned about 0.60% of Hologic worth $90,278,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Winnow Wealth LLC purchased a new stake in Hologic during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares in the last quarter. Root Financial Partners LLC acquired a new position in shares of Hologic during the third quarter worth $27,000. SJS Investment Consulting Inc. lifted its holdings in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the 2nd quarter worth $33,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $75.09 on Thursday. The company has a 50 day simple moving average of $74.89 and a two-hundred day simple moving average of $71.46. The stock has a market cap of $16.76 billion, a price-to-earnings ratio of 31.29, a PEG ratio of 2.24 and a beta of 0.72. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.36.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 EPS. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent analyst reports. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Morgan Stanley upped their price objective on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Two analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.